| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Development Officer
1 company
Marc Semigran last filed a Form 4 in December 2024, as Chief Development Officer at EWTX. Marc Semigran's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 6,716 shares of EWTX. The EWTX filings lean toward selling, a net 29,709 shares.
Marc Semigran has 4 Form 4 filings on record from December 2022 to December 2024, all as Chief Development Officer at Edgewise Therapeutics (EWTX), 2022–2024.
The 7 reported transactions were 4 option or other derivative awards, 2 open-market sales and 1 option exercise.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $882K.
The only open-market sale was 29,709 shares of EWTX at an average $29.69 on December 24, 2024, about $882K. Twelve months later EWTX was down 8%.
Shares as reported in the last Form 4 for each company; the most recent is from December 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.